Weaker-than-expected jobs data has bolstered investor expectations for another Federal Reserve interest rate cut in October, pushing major indices to record closes.
Investment giant advises 'conservative' allocation to digital assets for certain clients, signaling growing mainstream acceptance.
Conditional approval for Dectomax-CA1 addresses a significant threat to the U.S. livestock industry, boosting company shares.
The pharmaceutical giant is now considered one of Morningstar's highest-conviction undervalued stocks, citing a robust pipeline and strategic acquisitions.
Applied Materials forecasts a $600 million revenue hit, signaling broader disruption for the global chip industry amid escalating US-China tech tensions.
Strategic acquisition aims to bolster Firefly's national security and defense capabilities, expanding its space and defense mission services.
Early results for ARV-102, a novel PROTAC LRRK2 degrader, show the experimental therapy is well-tolerated and demonstrates key biomarker engagement.
Tecentriq and Zepzelca combination approved as first-line maintenance treatment for extensive-stage small cell lung cancer (ES-SCLC).